| abstract |
Provided herein are modified immunoglobulins comprising amyloid-reactive peptides linked to antibodies, as well as humanized antibodies and antibody-peptide fusion proteins that bind to human amyloid fibrils. Also provided herein are methods of treating amyloid-based diseases by administering modified immunoglobulins, humanized antibodies, or antibody-peptide fusion proteins. |